Roivant Sciences Ltd. - stock earnings
ROIV Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | 5.1 billion USD | 37.1 million USD |
| 2023Q3 | -304.3 million USD | 37.1 million USD |
| 2023Q2 | -291.8 million USD | 21.6 million USD |
| 2023Q1 | -175.4 million USD | 27.4 million USD |
| 2022Q4 | -384.9 million USD | 17.1 million USD |
| 2022Q3 | -315.9 million USD | 12.5 million USD |
| 2022Q2 | -353.8 million USD | 4.3 million USD |
| 2022Q1 | -291.3 million USD | 9.2 million USD |
| 2021Q4 | -284.5 million USD | 24.3 million USD |
| 2021Q3 | -208.5 million USD | 14.0 million USD |
| 2021Q2 | -82.2 million USD | 7.7 million USD |
| 2021Q1 | -509.6 million USD | 15.1 million USD |
| 2020Q4 | -261.0 million USD | 5.8 million USD |
| 2020Q3 | -35.4 million USD | 1.3 million USD |
| 2020Q2 | -3.2 million USD | 1.6 million USD |
ROIV Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -1.2 billion USD | 61.3 million USD |
| 2022 | -924.1 million USD | 55.3 million USD |
| 2021 | -900.2 million USD | 23.8 million USD |
| 2020 | 1.2 billion USD | 67.7 million USD |
| 2019 | -1.0 billion USD | 2.3 million USD |
ROIV
Price: $11.03
52 week price:
Earnings Per Share: 5.27 USD
P/E Ratio: -7.35
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 1.4 million
Market Capitalization: 9.2 billion